In the six anti-flotillin-1/2-positive patients in whom the antibody was found prospectively and for whom we could evaluate medical records, testing for anti-AQP4 and anti-MOG was initially requested based on clinically assessed NMOSD core characteristics like myelitis and/or optic neuritis [10]. The gene discussed is MOG; the disease is myelitis.